Boundless Bio amends Serapha merger deal to add pre-funded warrants, RSU conversion terms
BOLD•BOLD•BOLD•BOLD•The vote threshold to increase authorized Boundless Bio common shares shifts to a majority of shares cast.
Boundless Bio plans to merge its Merger Sub into Serapha Bio, leaving Serapha as a wholly owned subsidiary.
An Aug. 28, 2026 amendment clarified terms tied to Serapha’s pre-closing financing.
Serapha RSUs will convert into assumed RSUs for Boundless Bio common stock, adjusted by the exchange ratio.
Merger consideration may include pre-funded warrants at a $0.00001 exercise price to avoid breaching beneficial ownership limits.
